Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06157892CT.gov A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | — | Recruiting | — | — | — |
NCT05649163CT.gov Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastric Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Disitamab Vedotin (this asset) | Seagen, a wholly owned subsidiary of Pfizer | P2 | CCC · 53 |
| Rivoceranib | Jiangsu Hansoh Pharmaceutical Co., Ltd. | P4 | BBB |
| Fluorouracilum | I-Mab Biopharma US Limited | P4 | BB |
| Oxaliplatin | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Irinotecan | Shenzhen Xinhe Biomedical | P4 | BB |
| Epirubicin | Rondo Therapeutics | P3 | BB |
| Capecitabine | I-Mab Biopharma US Limited | P3 | BB |
| Docetaxel | Jiangsu Hansoh Pharmaceutical Co., Ltd. | P3 | BB |
| Pembrolizumab | Eikon Therapeutics | P3 | BB |
+42 more in the Gastric Cancer cohort
Other indications for Disitamab Vedotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastroesophageal Junction Adenocarcinoma | — | P2 | BB · 67 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 64 |
| Colorectal Cancer | — | P4 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Disitamab Vedotin in Gastric Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/disitamab-vedotin-gastric-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →